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marked murine ES cells (R1/129) and ES-CCE without marker
ﬂuorescence protein in vitro differentiation induced by TGF- (2
ng/ml), EGF (25 ng/ml), and -FGF (100 ng/ml) for 7 days.
IL10/ mice were injected with predifferentiated ES-YFP cells
and killed at 2 months postinjection. Serial frozen sections of
colon, small intestine, and thymus were made, and EYFP staining
was double detected using a confocol microscope and determined
by immunohistochemistry using anti-GFP antibody. Results:His-
topathologic analysis demonstrated improvement in colon tissue.
Fluorescent and confocal microscopy demonstrated presence of
the ES-EYFP cells in the colon, small intestine, liver, and thymus
tissues. Anti-GFP staining was also detected in these tissues. The
EYFP signal was not detected in sham and control IL10/
knock-out mice. Immune studies by ELISA demonstrated a
TH13TH2 shift suggesting immune recovery. Conclusion: Our
results suggest that the study of differentiation and repair potential
of embryonic stem cells in pathological Crohn’s disease model may
lead to an alternative therapeutic potential for the treatment and
prevention of inﬂammatory bowel disease.
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HUMAN HEMATOPOIETIC STEM CELLS CAN BE EXPANDED EX VIVO
USING RECOMBINANT TAT-HOXB4 PROTEIN
Krosl, G.1; Giard, M.-P.1; Krosl, J.2; Humphries, R.K.3; Sauvageau,
G.2; Roy, D.C.1 1. Hopital Maisonneuve-Rosemont Research Centre,
Montreal, QC, Canada; 2. IRIC/Universite de Montreal, Montreal,
QC, Canada; 3. Terry Fox Laboratory, BC Cancer Agency, Vancouver,
BC, Canada.
In mouse bone marrow transplantation models, engineered over-
expression of HOXB4 has been one of the most potent stimulator
of hematopoietic stem cell (HSC) expansion identiﬁed to date. The
addition of soluble recombinant TAT-HOXB4 protein was also
recently reported to enable rapid in vitro expansion of murine
HSCs that retain their in vivo proliferation and differentiation
capacity. However, the expansion potential of TAT-HOXB4 has
always been tested on murine cells, and the capacity of this recom-
binant protein to expand human hematopoietic stem cells has
remained hypothetical. To determine the ability of recombinant
TAT-HOXB4 protein to promote human HSC expansion, we
performed a series of experiments using CD34 populations iso-
lated from healthy volunteers. The CD34 cell populations were
cultured for 4 days in ex vivo 15 medium supplemented with stem
cell factor (300 ng/mL) and G-CSF (50 ng/mL) in the presence or
absence of TAT-HOXB4 protein (50 nmol/L). In response to
TAT-HOXB4, total numbers of mononuclear cells demonstrated a
modest but distinct 2-fold increase compared with controls. TAT-
HOXB4 treatment had a major proliferation enhancing effect on
the more primitive cell populations such as CFU-GEMM, BFU-E,
and BFU-Meg, which numbers increased 26.5- 	 1.4-fold
(mean 	 SD), 2.2- 	 0.7-fold, and 2.1- 	 0.2-fold, respectively,
over their input values, and 19.1- 	 1.3-fold, 2.7- 	 0.7-fold, and
31- 	 3.4-fold, respectively, compared with growth factor-only
controls. In response to TAT-HOXB4, the total numbers of
CD34CD38Lin cells increased 2.1- 	 0.7-fold above their
starting numbers, compared with a 1.5- 	 0.5-fold loss of this
population in control cultures. HSC numbers were enumerated at
the beginning, and after a 4-day TAT-HOXB4 treatment period
under the same conditions using a NOD/SCID repopulation assay.
In response to 50 nM TAT-HOXB4, NOD/SCID repopulating
cell (SRC) numbers increased 2-fold over their input values, com-
pared with a 9-fold loss in control cultures without TAT-HOXB4.
These results show that recombinant TAT-HOXB4 protein, even
when combined with a limited number of hematopoietic growth
factors, has the capacity to rapidly induce ex vivo expansion of
human stem cell and progenitor cell populations. They also pro-
vide the ﬁrst evidence that TAT-HOXB4 protein could be used to




ABDOMINAL CT IN THE CLINICAL EVALUATION OF ACUTE GRAFT-
VERSUS-HOST DISEASE (GVHD) OF THE GASTROINTESTINAL TRACT:
DIFFUSE SMALL INTESTINE INVOLVEMENT IS ASSOCIATED WITH POOR
OUTCOME
Shimoni, A.; Hertz, M.; Yeshurun, M.; Portnoy, O.; Hardan, I.;
Amitai, M.; Nagler, A.; Apter, S. Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
Acute GVHD is the major treatment-related complication after
allogeneic stem-cell transplantation. Acute GVHD of GI tract is a
clinical diagnosis supported by histopathologic ﬁndings. The vol-
ume of diarrhea determines disease stage and prognosis; however,
its assessment is inconvenient and inaccurate. Moreover, patients
may present with atypical symptoms, whereas GI tract biopsies
may be falsely negative due to patchy involvement or may be
contraindicated in patients with severe thrombocytopenia. This
study was designed to determine the CT features associated with
acute GI GVHD and to evaluate its role in assessment of severity
and prognosis. A total of 34 consecutive patients with symptoms
suggestive of acute GI GVHD were evaluated by abdominal CT.
Of these 34 patients, 18 had clinical stage I-II and 14 had clinical
stage III-IV by the Glucksberg criteria; 32 patients had patholog-
ical ﬁndings on CT. The most consistent ﬁnding was thickening of
the bowel wall, which was limited to the small bowel (n  11) or
large bowel (n  5) or involved both segments (n  16). Involve-
ment was diffuse or segmental. Other manifestations included
intestinal dilatation (n  11), mucosal enhancement (n  3), and
gastric wall thickening (n  7). Extraintestinal ﬁndings included
mesenteric stranding (n  22), ascites (n  13), and biliary system
abnormalities (n  11). Ten patients had urinary excretion of
orally administered gastrograﬁn, which is not normally absorbed
by an intact intestine. Diffuse thickening of the small bowel wall
and/or any involvement of the large intestine were patterns asso-
ciated with severe clinical presentation. Eleven and 14 of the 16
patients with clinical stage III-IV had these patterns, compared to
5 and 7 of the 18 patients with stage I-II, respectively (P  .03).
Overall, 19 patients responded to immunesuppressive therapy.
Nine patients are alive; 25 died, 13 of complications directly re-
lated to GVHD. Diffuse small bowel disease was associated with
poor prognosis. Only 6 of 16 patients showing this pattern re-
sponded to therapy, compared with 13 of 18 patients without this
pattern (P  .05). The cumulative incidence of GVHD-related
death was 56% and 25%, respectively (P  .05). Overall survival
was not signiﬁcantly different in the 2 groups. In conclusion,
abdominal CT may have an important role in the diagnosis of
GVHD in atypical presentations and in the prognostic evaluation.
Diffuse small intestinal disease is associated with poor response to
therapy and GVHD-related mortality. CT ﬁndings may direct the
clinician in determining the therapeutic approach.
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SAFETY AND TOLERABILITY OF ANTIBACTERIAL PROPHYLAXIS DUR-
ING THE POSTENGRAFTMENT PHASE AFTER MYELOABLATIVE HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION
Bubalo, J.S.; Hayes-Lattin, B.; Curtin, P.T.; Leis, J.F.Mauro, M.J.;
Simic, A.Dunn, A.; Subbiah, N.; Allen, B.; Balleison, S.; Schubach, S.;
Maziarz, R.T. Oregon Health Science University Hospital, Portland,
OR.
Background: Bacterial infections are frequent complications of
the postengraftment phase after ablative allogeneic HSCT. This
pilot study investigated the safety and tolerability of administering
antibiotic (ABX) prophylaxis from when patients tolerated PO
medications after engraftment (ANC  1500/mm3 for 2 days)
through day 100. Methods: Twenty-three engrafted allogeneic
BMT patients at OHSU, received moxiﬂoxacin (MOXI) 400 mg
po daily. Drug was started on discontinuation of any ABX used for
the treatment of pre-enrollment bacterial infection or neutropenic
fever. Rates of bacterial infection, bacteremia, and colonization
were recorded. Comparisons were made with a cohort of 60 con-
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secutive patients undergoing ablative BMT at OHSU without ABX
prophylaxis from 2001 to 2002. Results: The median duration of
MOXI prophylaxis was 77 days (range, 7–87 days). Five patients
had dose interruptions, 4 due to nausea associated with GVHD,
and 1 patient withdrew from the study. Three patients had dose
interruptions during empiric ABX therapy for possible bacterial
infection. Overall, MOXI was well tolerated in this patient popu-
lation, with 5 episodes of grade 3/4 toxicity possibly related to
study drug (2 orthostatic hypotension in 1 patient, 2 nausea, and 1
hypertension). Five patients had episodes of transaminitis that were
unlikely to be due to the study medication and that responded to
discontinuation of azole antifungal therapy (4) or to treatment of
liver GVHD (1). No cardiac arrhythmias were observed. Com-
pared with historic controls, a marked decrease in postengraftment
bacterial infections was observed. In the control cohort, 16 patients
experienced 17 episodes of Gram-negative infections and 22 pa-
tients had 25 episodes of symptomatic Gram-positive infections
during the postengraftment phase without prophylaxis. In contrast
with MOXI prophylaxis, 2 patients experienced 3 Gram-negative
infections (2 test, P  .079), 1 patient had an anaerobic infection,
and 7 patients had 9 symptomatic Gram-positive infections. Two
breakthrough bacteremias with Streptococcus viridans occurred and
were treated successfully. ABX MICs of Gram-negative isolates
showed P. putida sensitive to MOXI and C. freundii resistant, both
without drug efﬂux. Conclusions: Prophylactic MOXI dosed
throughout the postengraftment phase has been well tolerated,
safe, and associated with fewer bacterial infections compared to
historic controls. The efﬁcacy of this prophylaxis strategy will be
determined in a planned randomized, placebo-controlled trial.
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HEMATOLOGIC EFFECTS OF LINEZOLID IN FEBRILE NEUTROPENIC
PATIENTS
Jaksic, B.1; Hartman, C.S.2; Leonard, L.B.2; Tack, K.J.2 1. Merkur
University Hospital, Zagreb, Croatia; 2. Pﬁzer Inc., Ann Arbor, MI.
Linezolid (LZD) is an oxazolidinone antibacterial effective for
the treatment of infections caused by Gram-positive pathogens
including methicillin-resistant Staphylococcus spp., glycopeptide-re-
sistant Enterococcus spp., and multi-drug resistant Streptococcus pneu-
moniae. Hematopoietic suppression is a side effect associated with
several classes of antibiotics. Linezolid has been associated with
reversible thrombocytopenia and anemia, predominately in pa-
tients with serious infections treated beyond the recommended 28
days. In patients receiving myelosuppressive chemotherapy, addi-
tional bone marrow suppression may have clinical signiﬁcance.
The effect of LZD on platelet (PLT) and white blood cell (WBC)
recovery and on hemoglobin (HGB) levels was assessed compared
with vancomycin (VAN) in febrile neutropenic oncology patients.
Methods: LZD was compared with VAN in a randomized, dou-
ble-blind, multicenter trial. Oncology patients with febrile neutro-
penia (absolute neutrophil count  500/mm3) and a proven or
suspected Gram-positive infection received LZD (600 mg) or
VAN (1 g) intravenously every 2 hours for 10–28 days. Laboratory
values were checked at deﬁned times, including end-of-therapy
(EOT) and follow-up (FU), 7 days posttherapy. Results: 605
patients were treated (304 LZD, 301 VAN); treatment groups were
similar with respect to demographics, comorbidities, severity and
type of illness, and duration of neutropenia. Hematologic/lym-
phatic cancers were the most common in both groups (95.4%
LZD; 93.7% VAN). Average duration of treatment was similar
between groups (LZD, 11.4 days; VAN, 11.5 days). Overall mor-
tality rate at 16 days posttherapy was 5.6% for LZD versus 7.6%
for VAN (P  .31). Overall clinical success rates at FU were
comparable between LZD and VAN (57.0% vs 52.9%; P  .32).
Mean (	SD) values for HGB, PLT, WBC, and ANC at baseline
(BL), EOT, and FU were as follows. Incidence of complications
related to bleeding was similar in the groups (34 reports for LZD
and 38 for VAN) and were reported for 1% of patients in either
group with the exception of epistaxis (3.3% for LZD, 5.0% for
VAN) and petechiae (1.7% for LZD, 1.0% for VAN). Conclu-
sions: LZD did not suppress recovery of PLT counts when com-
pared with VAN and did not have an effect on HGB or WBCs.
Treatment did not result in increased incidence of events related to
bleeding. LZD is a reasonable therapeutic option for the treatment
of febrile neutropenic oncology patients with proven or suspected
Gram-positive infections.
BL EOT* FU*
HGB LZD 8.8 (1.6) 9.4 (1.5) 10.0 (1.6)
g/dL VAN 8.8 (1.6) 9.3 (1.5) 10.0 (1.7)
PLT LZD 28 (31) 75 (116) 141 (148)
K/mm3 VAN 32 (54) 75 (99) 150 (165)
WBC LZD 0.77 (2.4) 3.85 (5.2) 4.79 (5.2)
K/mm3 VAN 1.18 (9.0) 4.39 (5.5) 5.12 (6.5)
ANC LZD 0.12 (0.34) 2.48 (4.14) 2.99 (4.41)
K/mm3 VAN 0.11 (0.29) 2.79 (4.36) 2.93 (3.59)
*Statistical signiﬁcance not observed between groups for mean
change from baseline
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IMMUNOPATHOGENIC MECHANISMS OF ACUTE POST-HSCT LUNG IN-
JURY: A SYNGENEIC MURINE MODEL INDUCED BY OCCULT PNEUMO-
CYSTIS CARINII INFECTION AND TBI
Bruckner, L.; Finkelstein, J.; Gigliotti, F. University of Rochester Med-
ical Center, Rochester, NY.
Pulmonary toxicity is a major complication of HSCT and the
leading cause of early post-HSCT mortality. Various lung insults
have been implicated in the pathogenesis of post-HSCT lung
injury in association with speciﬁc therapies or patient populations.
Such lung insults are thought to act additively, whereby several
insults together produce injury not anticipated with any one alone.
We have developed a dual hit murine model of lung injury after
syngeneic HSCT in which subclinical infection with Pneumocystis
carinii sp. muris (Pc) produces an inﬂammatory response that sen-
sitizes the lung to the damaging effects of TBI. Mice infected with
Pc 7 days before receiving TBI and a syngeneic HSCT developed
a severe interstitial pneumonitis that was not seen in animals who
were treated with either Pc infection or TBI alone. Pulmonary
dysfunction was evident as early as 12 days post-HSCT and was
marked by signiﬁcant weight loss, increased respiratory rate, and
decreased dynamic lung compliance. The resultant inﬂammation
was characterized by large numbers of eosinophils and lympho-
cytes in the BALF, with a progressive inﬂux of lymphocytes pre-
dominated by CD8 T cells. In vivo depletion of both CD4 and
CD8 T cells abrogated the pulmonary compromise and inﬂam-
mation, suggesting that this process is T-cell dependent. The lung
injury observed in this model was not attributable to direct damage
caused by Pc, because average Pc lung burdens were actually 1 log
higher in the T-cell-depleted animals, who exhibited no pulmo-
nary compromise. Finally, the severity of disease appears to be
associated with increased expression of TNF-, as well as other
immune-modulating cytokines, such as IFN-. We hypothesize
that TNF- is central in mediating the observed synergy of these
detrimental lung effects and that T cells are critical in driving the
inﬂammatory response that results in bystander lung injury.
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